


Scientific Report

2013



INSTITUT DE RECERCA CONTRA 
LA LEUCÈMIA **JOSEP CARRERAS**
Per un futur sense leucèmia

Headquarters

C/ Muntaner, 383 3r. 08021
Barcelona
Tel. (+34) 93 414 55 66

For any matter concerning this report
please contact:
comunicacio@carrerasresearch.org

The report can also be downloaded
from:
<http://www.carrerasresearch.org>

Publisher, layout and typesetting

Josep Carreras Leukaemia Research
Institute

Photography

Photographic archives of the Josep
Carreras Leukaemia Foundation and
the Josep Carreras Leukaemia
Research Institute



I recovered from leukaemia thanks to the extraordinary work of the doctors and nurses who looked after me. Like many grateful patients, I also benefited from the perseverance of scientists searching for a cure for this disease.

Since the day we were established we have always offered financial assistance for research, through grants, university funding and, mainly, by providing funding for projects and the creation of laboratories and other scientific infrastructures.

We can not stop until leukaemia becomes a totally curable disease. The creation of the Josep Carreras Leukaemia Research Institute is the latest sign of what drives us forward: our unceasing determination to battle against this disease until we defeat it.

Thanks to the extraordinary team of doctors, experts in life sciences, the support of the Generalitat de Catalunya, and the solidarity of our generous donors, our Institute is now a reality.

I would like to thank you for your interest in our institution and invite you to join us in our crusade.

*Josep Carreras
President Board of Trustees
Josep Carreras Leukaemia Research Institute (IJC)*



Contents

**About us**

Welcome

Who we are and what we do

Mission, vision and values

Our team

Governing bodies

Organisational chart

Human resources

Financial data

Income statement

Balance sheet

Fundraising

Scientific activities

Research groups

Research projects

Technology platforms

Clinical trials

Scientific production

Publications

Impact factors

Training activities

Graduate and post-graduate

Theses read

Seminars and sessions

Courses and congresses

Cooperation

Agreements

Institutions involved

Communication

Scientific dissemination

Institutional events



About us



Welcome



Once again the IJC's annual report is testimony to the excellent research being carried out at the three Josep Carreras campuses. Our congratulations are due, therefore, to everyone for their magnificent work and scientific rigour.

2013 was a year in which progress was made in the fight against leukaemia. It was a year of combined scientific efforts, continuing cooperation and commitment to society.

A centre totally capable of synchronising research, health care, innovation and teaching, something of fundamental importance for achieving scientific excellence.


Highlights of the IJC's leadership are the construction of the new building in Badalona and the agreements about the SUMA project between the Germans Trias Institute (IGTP) and the Institute for Predictive and Personalised Cancer Medicine (IMPPC).

With all this in mind, I would like to invite you to discover more from the following pages about the activities in 2013, activities which have earned this centre a leading position in biomedical research to confront leukaemia.

Evarist Feliu
President of the Delegate Committee
Josep Carreras Leukaemia Research
Institute (IJC)

Who we are and what we do

The Josep Carreras Leukaemia Research Institute (IJC), a Generalitat de Catalunya Research Centre (CERCA), was established with the aim of promoting biomedical research into, and the development of, personalised medicine in the field of malignant blood diseases, especially leukaemia. It is a centre without precedent which, with the work and dedication of researchers from around the world, uses the most innovative technologies to try to vanquish leukaemia and other malignant blood diseases.



The IJC has three independent and coordinated scientific campuses: the Hospital Clínic-UB Campus, located at the research facilities of Barcelona's Hospital Clínic, and those of the University of Barcelona (UB) Faculty of Medicine; the Catalan Institute of Oncology/Germans Trias i Pujol Campus in Badalona, located near the Germans Trias i Pujol University Hospital and its research foundation and the Autonomous University of Barcelona (UAB) Germans Trias i Pujol Teaching Unit; and thirdly, the Sant Pau Campus and its research foundation, located within the health care facilities of the Hospital de la Santa Creu i Sant Pau and the UAB's Sant Pau teaching unit. The IJC's Hospital Clínic-UB Campus reaffirms the UB Faculty of Medicine and the Hospital Clínic's scientific commitment to excellence in the field of hematology, which commenced with the work of Prof. Farreras Valentí and which has been able to continue thanks to the extraordinary work carried out by Prof. Ciril Rozman and those who studied under him.



Mission

Our mission is to carry out research into the basic, epidemiological, preventive, clinical and transferable aspects of leukaemia and other malignant blood diseases.

Vision

The Josep Carreras Leukaemia Research Institute's vision is for the research it does to identify new therapeutic targets that will make it possible to develop more precise and less aggressive treatments. We aspire to understanding the origin and development of leukaemias and other malignant blood diseases in order to prevent them. We are working so that, in the future, all leukaemias will be curable.

Values

Altruism

We are inspired by the example of Josep Carreras and the professional staff he has chosen to found the Institute that bears his name. Financial donations, be they public or private, are used in the most efficient way by simplifying administrative procedures and reducing the secondary costs of our main mission.

Sharing

We take full advantage of all possible synergies, we promote continuing cooperation, the creation of new alliances and group work. We also promote the dissemination of information about leukaemia and encourage citizen participation.

Talent

We aspire to attracting, promoting and creating talent.

Perseverance

We will continue until all leukaemias can be cured.

Respect

We protect the dignity and respect the rights of everyone who has a relationship with the Institute, especially those who collaborate on our projects. Our work is as stalwart as the patients and families who participate in the project, and our sponsors and staff.



Our team



Governing bodies

The highest governing body is the Board of Trustees, on which are represented: the Josep Carreras Foundation, the Catalan Government Ministry of Business and Knowledge, the Catalan Government Ministry of Health, the Autonomous University of Barcelona (UAB), the University of Barcelona (UB), Badalona Town Council, the Directorate General for Health Research and Planning, the Catalan Institute of Oncology, the Northern Metropolitan Territorial Area Administration, the Catalan Foundation for Research and Innovation, the Hospital Clínic/August Pi i Sunyer Institute for Biomedical Research (Idibaps), the UB Hospital Coordination Committee and the Research Centres of Catalonia Institution Foundation (ICERCA).

Board of Trustees

President

Mr. Josep Carreras Coll

President of the Josep Carreras Foundation and the Josep Carreras Leukaemia Research Institute

First Vice-president

Catalan Government Minister of Business and Knowledge

Second Vice-president

Catalan Government Minister of Health

Members

Rector Autonomous University of Barcelona (UAB)
Rector University of Barcelona (UB)

Mayor of Badalona

Director General for Research, Catalan
Government Ministry of Business and Knowledge

Director General for Health Research and Planning

Deputy Director General for Health Research and
Innovation

Director General Catalan Institute of Oncology

Administrator Northern Metropolitan Territorial Area

Secretary for Universities and Research, Catalan
Government Ministry of Business and Knowledge

Director Catalan Foundation for Research and
Innovation

Research Director Hospital Clínic - IDIBAPS

Treasurer of the Josep Carreras Leukaemia
Foundation

Vice-president of the Josep Carreras Leukaemia
Foundation

Trustee of the Josep Carreras Leukaemia
Foundation

Administrator of the Josep Carreras Leukaemia
Foundation

Vice-rector for Research and Transferability,
Autonomous University of Barcelona (UAB)

University of Barcelona Hospital Coordination
Committee

Secretary

Director of the Research Centres of Catalonia
Institution Foundation (ICERCA)



Delegate committee

President

Prof. Evarist Feliu,
Coordinator of the ICO-Germans Trias i Pujol
Campus

Members

PRICS coordinator, Catalan Government Ministry of
Health

Director General, Catalan Government Ministry of
Health, Directorate General Health Resources
Planning Regulation

Directorate General for Research, Catalan
Government Ministry of Business and Knowledge

Director iCerca, CERCA Institution, Research
Centres of Catalonia

Administrator, Josep Carreras International
Foundation

University of Barcelona Commissioner for Hospital
Coordination

Vice-rector for Strategic Projects and Planning,
Autonomous University of Barcelona

CoExternal Scientific Committee

President

Prof. Lucio Luzzatto, Instituto Toscano Tumori
Firenze

Members

Prof. Robert Sackstein, Dana-Farber/Harvard
Cancer Center Boston

Prof. Francesco Lococo, Università degli Studi di
Roma "Tor Vergata"

Prof. Alberto Orfao, CIC Centro de Investigación del
Cáncer Salamanca.

Prof. Brigitte Schlegelberger, University of
Hannover

Internal Scientific Committee

UB-Clínic Campus

Álvaro Urbano Ispizúa (Internal Scientific
Committee Coordinator)

Pablo Menéndez (Campus Research Director)

Jordi Esteve Reyner

Armando López Guillermo

Joan Bladé Creixentí

Francisco Cervantes Requena

ICO-GTiP Campus

Evarist Feliu Frasnado (President of the Delegate
Committee)

Francesc Solé (Campus Research Director)

Josep M^a Ribera Santasusana

Lurdes Zamora Plana

José Tomás Navarro Ferrando

Juan Manuel Sancho Cía

Sant Pau Campus

Jordi Sierra

Josep Nomdedeu


Joan Carles Souto

Ramon Mangues

Carol Moreno



Organisational chart



Scientific directors



ICO-GTP Campus
Francesc Solé




Clinic-UB Campus
Pablo Menéndez




Sant Pau Campus
Jordi Sierra

	IJC ICO Germans Trias UAB	IJC Clínic UB	IJC Sant Pau UAB	IJC Shared
Lead researchers	1	2		
Pre-doctoral researchers	3	5		
Post-doctoral researchers	1	5		
Support staff	2	4		
Management and administration staff	1			11
General services and maintenance				
Staff professionally linked with the IJC	7	16		11
Staff professionally linked with the Hospital	28	14	8	





At the three hospitals where the IJC has a presence there has always been a great willingness to participate in clinical research. And there are clinics with a very considerable background in basic sciences. Integration, in this respect, must therefore not be just a question of maintaining present levels, but of increasing them in order to enhance the added value it represents in both the health sciences and in clinical practice.





Financial data

Income statement

In 2013 there was an increase of more than 230% in income from the capture of public funds and the provision of services.

With regard to expenses, 50% of the IJC's outlay corresponds to staffing. There was a increase in total expenses of 250%, corresponding to the incorporation of new staff. At this early stage the evolution of income, expenses and investments gives a negative result of €130,661.49.



	2013
Income from activities	€1.159.986,81
Services rendered	€101.887,79
Official subsidies for activities	€791.874,77
Other subsidies. donations...	€266.224,25
Self-constructed assets	€59.506,29
Supplies	-€266.434,80
Other income from activity	
Staff costs	-€606.626,17
Wages and salaries	
Social security expenses	
Other expenses	-€323.289,77
External services	-€272.536,62
Taxes	-€3,15
Losses. depreciation...	
Other current period losses	-€50.750,00
Fixed asset depreciation	-€170.851,99
IJC Subsidy	€20.841,74
Other income	€249,52
OPERATING INCOME	-€126.618,37
Financial income	€1.367,51
Financial expenses	-€4.906,54
Subsidy return expenses	
Exchange rate differences	-€504,09
Financial result	-€4.043,12
Surplus / deficit before tax	-€130.661,49
Tax on profit	
SURPLUS / DEFICIT OF THE FINANCIAL YEAR	-€130.661,49


Balance sheet

ASSETS	2013
Non-current assets	€4.135.233,70
Intangible fixed assets	€2.262.756,67
Tangible fixed assets	€1.841.497,75
Long-term investments in group and associated entities	€0,00
Long-term financial investments	€30.979,28
Current assets	€2.242.398,23
Stock	
Users, sponsors and other debtors from activities	€1.595.717,09
Other credits with the public administration	
Short-term financial investments	
Short-term accruals	€1.687,27
Cash and others	€644.993,87
TOTAL ASSETS	€6.377.631,93

LIABILITIES	2013
Net assets	€2.130.941,60
Equity	€857.188,17
Start-up funds	€986.342,90
Special funds	
Profit or loss from previous years	€1.506,76
Year profit or loss	-€130.661,49
Subsidies, donations and legacies	€1.273.753,43
Non-current liabilities	€1.279.765,13
Long-term debt	€1.279.765,13
Current liabilities	€2.966.925,20
Short-term provisions	
Short-term debt	€1.109.012,32
Creditors for activities and others	€1.394.548,90
Short-term debts with group and associated entities	€9.913,13
Current tax liabilities and other debts with the public administration	
Short-term accruals	€453.450,85
TOTAL (LIABILITIES + NA)	€6.377.631,93



Evolution of income






Scientific activity



Research groups



Research projects

IP	Projects 2013	Amount
Eulalia Genesca	Tecnico apoyo ISCIII	€49.500,00
Clara Bueno	Miquel Servet ISCIII	€151.053,00
Alvaro Urbano	Infraestructuras MINECO	€450.000,00
Clara Bueno	ISCIII AES PIS	€146.077,00
Damià Romero	ISCIII PFI	€53.629,00
Pablo Menendez	Era net ISCIII	€112.000,00
		€962.259,00





Competitive funding granted

	ICO Germans UAB	Clínic UB
Active projects (national)	3	6
Projects awarded (national)	1	5
Projects tendered (national)		
Active projects (international)		1
Projects awarded (international)		1
Projects tendered (international)		
Projects awarded (public)	1	6
Projects awarded (private)	5	8
Active research networks	1	
Research networks awarded		
Competitive funding granted (€)	€49.500,00	€962.259,00
Non-competitive funding granted (€)	€85.755,00	€346.919,00
Sum total competitive and non-competitive overheads granted	€99.907,00	€205.950,00



Technology platforms

Cytogenetics platform

The Josep Carreras Leukaemia Research Institute cytogenetics platform is directed by Dr. Francesc Solé. The platform includes the Catalan Institute of Oncology's (ICO) Cytogenetics Laboratory and the 32K Bacterial Artificial Chromosome (BAK) library.

Affymetrix Microarrays Platform

The Affymetrix® Microarrays Platform (AMP) is a service focused on microarray DNA and RNA solutions provided by Affymetrix. The main aim is to find solutions, based on basic research, applied research and diagnosis, that lead towards personalised medicine.

Blood cancer samples

The administration of the collection, processing and storage of blood cancer samples. These samples are stored in a collection called 'Collection of samples from patients with hematologic neoplasms'.

Fluidigm Platform

The Fluidigm platform is used to create integrated fluid circuits (IFCs) which are single-use biochips which automate PCR reactions using the volumes of nanolitres from two samples and reagents to produce consistent results.







Clinical trials

Clinical trials are a fundamental part of our research. In this regard, the IJC evaluates treatments, the efficacy of drugs, and the suitability of equipment.

It enables new treatments to be tested to prevent, relieve or cure diseases.






Scientific production




Publications

Indexed articles



Global impact factor





Teaching activities



Teaching

The IJC provides a high-quality teaching programme for students, scientists, technicians and others with an interest in achieving a solid and up-to-date grounding in the field of leukaemia and malignant blood diseases.

The IJC organises a Doctorate in Hematology, a Master's degree in malignant blood diseases and it participates in the teaching for degrees in medicine and biomedicine.

In 2013 the following theses were presented at the IJC:

Clinical-biological characterization of myelodysplastic syndromes with deletion 5q

Doctoral student: Mar Mallo Fajula. UAB.

Director: Francesc Solé

Badalona, June 2013

Cytogenetic Characterization of Splenic Lymphoma of the Marginal Zone

Doctoral student: Marta Salido. UAB.

Director: Francesc Solé

Barcelona, October 2013



Training

The IJC organises complementary training activities at all levels, from scientific conferences, monthly seminars and technology sessions, to specialised courses.

Training courses

3

Scientific conference

1

Scientific seminars

16

Internal sessions

MDS GRUP
FRANCESC SOLE

Mar Mallo
Vera Ademà

MPN GROUP
LURDES ZAMORA, BLANCA XICOY

Laura Palomo

GLICOLSILATION GROUP
FUMI YAMAMOTO

Emili Cid

ALL GROUP
JM RIBERA

Eulalia Genescà
Jordi Ribera

IRON GROUP
MAYKA SANCHEZ

Jorge Couso

CHROMATIN GROUP
MARCUS BUSCHBECK

Roberto Malinvemi
Julien Douet





Courses

Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.

Directors: Francesc Solé. In collaboration with: Mar Mallo, Vera Ademà, Laura Palomo. Blanca Espinet, Marta Salido.
Badalona, May 2013

Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.

Directors: Francesc Solé. In collaboration with: Mar Mallo, Vera Ademà, Laura Palomo. Blanca Espinet, Marta Salido.
Badalona, May 2013

Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.

Directors: Francesc Solé. In collaboration with: Mar Mallo, Vera Ademà, Laura Palomo. Blanca Espinet, Marta Salido.
Badalona, June 2013

CUBIMOL. Paper: Cytogenetic and genetic changes in myelodysplastic syndromes.

Speaker: Francesc Sole
Madrid, September 2013





Cooperation



Agreements

The IJC makes a great effort to establish continuing cooperation agreements, and it focuses on broadening its strategic alliances and agreements with the pharmaceutical industry, as well as other private organisations.

At the present time the following institutions are connected with the IJC:





Communication



Communication

The IJC knows that it is of prime importance to tell people about the work we do if we are to strengthen our bonds with society and its citizens. The desire to integrate social corporate responsibility into our management model is closely linked to the organisational values of the Josep Carreras Foundation.

To this end, the IJC has actively participated in scientific dissemination and in the creation of scientific vocations.

Scientific conference at the Josep Carreras Leukaemia Research Institute



Science week, Badalona town council



18a setmana de la ciència
del 15 al 24 de novembre

informació: tel. 932 687 700
www.fundacioerca.cat/setmanaciencia
@recercat #SC13cat

Organitzador:
Generalitat de Catalunya

Col·laboradors:
Fundació Josep Carreras per a la Recerca en Hematologia i Oncologia

Col·laboradors:
Universitat de Barcelona
Universitat de Girona
Universitat de Lleida
Universitat Rovira i Virgili

Patrocinadors:
Telefonos
guàrdia
feroce
ESTEVE
LABSUD
NOKIA

Patrocinadors:
SEAT
Caja Mutua de Seguros La Salut de Barcelona

Patrocinadors:
ESTEVE
Borja
Tel·lencat (el)

Patrocinadors:
Fica Orlans
la Caixa





Headquarters

C/ Muntaner, 383 3r. 08021
Barcelona
Tel. (+34) 93 414 55 66

For any matter concerning this report
please contact:
comunicacio@carrerasresearch.org


The report can also be downloaded
from:
<http://www.carrerasresearch.org>

Publisher, layout and typesetting

Josep Carreras Leukaemia Research
Institute

Photography

Photographic archives of the Josep
Carreras Leukaemia Foundation and
the Josep Carreras Leukaemia
Research Institute



Scientific Report IJC 2013



INSTITUT DE RECERCA CONTRA
LA LEUCÈMIA **JOSEP CARRERAS**
Per un futur sense leucèmia